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Background: Pulmonary arterial hypertension (PAH) is a rare condition that can ultimately lead to right heart failure
and death. In this study we estimated the health care costs and resource utilization associated with PAH in a large
US managed care health plan.
Methods: Subjects with claims-based evidence of PAH from 1/1/2004 to 6/30/2010 (identification period) were
selected. To be included in the final PAH study sample, subjects were required to have ≥2 claims with a primary
PH diagnosis; ≥2 claims with a PAH related-diagnosis (connective tissue diseases, congenital heart diseases, portal
hypertension); and ≥1 claim with evidence of a PAH-indicated medication. The earliest date of a claim with
evidence of PAH-indicated medication during the identification period was set as the index date. Health care costs
and resource utilization were compared between an annualized baseline period and a 12 month follow-up period.
Results: 504 PAH subjects were selected for the final study cohort. Estimated average total health care costs
were approximately 16% lower in the follow-up period compared to the baseline period (follow-up costs = $98,243
[SD = 110,615] vs. baseline costs = $116,681 [SD = 368,094], p < 0.001), but substantively high in each period relative to
costs reported for other chronic diseases. Pharmacy costs were significantly higher in the follow-up period vs. the
baseline period, ($38,514 [SD = 34,817] vs. $6,440 [SD = 12,186], p < 0.001) but medical costs were significantly
lower in the follow-up vs. baseline ($59,729 [SD = 106,683] vs. $110,241 [SD = 368,725], p < 0.001). These costs
were mirrored in health-care resource utilization estimates. The average counts of ambulatory visits and inpatient
stays were lower in the follow-up vs. the baseline (both p < 0.001). Results varied in exploratory analyses when less
restrictive subject identification algorithms were used.
Conclusions: Subjects with evidence of PAH had substantively high health care costs. Medical costs appeared
to decrease following PAH medication use, but with a concomitant increase in pharmacy costs.
Keywords: PAH, Costs, Resource use, Retrospective, Managed care, Pulmonary arterial hypertensionBackground
Pulmonary arterial hypertension (PAH) is one of five
groups of pulmonary hypertension (PH) classified by the
2009 European Society of Cardiology and European
Respiratory Society guidelines [1]. PAH is characterized
by constriction of pulmonary arteries and an increase in
pulmonary vascular resistance, leading to right heart fail-
ure [2]. Abnormal proliferation of smooth muscle and* Correspondence: Jesse.Potash@optum.com
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unless otherwise stated.endothelial cells is thought to play an important role in
disease pathology [3]. The hemodynamic profile of
PAH is described as a mean pulmonary arterial pressure
of 25 mmHg or higher, and a pulmonary capillary wedge
pressure of 15 mmHg or lower [4]. Within the PAH cat-
egory, several subgroups of disease are recognized, includ-
ing idiopathic PAH, heritable PAH (links to genetic
mutations in BMPR2 [5] and ALK-1 [6] have been found),
connective tissue disease-associated PAH (e.g., PAH
associated with systemic sclerosis or systemic lupus
erythematous), PAH associated with congenital heart dis-
ease, and portopulmonary hypertension [7]. DiagnosingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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challenging, and is facilitated by classification guidelines
[8]. Diagnosis of PAH has been found to be more com-
mon among women than men [9], and survival among
PAH patients has been reported at 83% at 1 year and 58%
at 3 years [10].
Symptoms of PAH include dyspnea on exertion, fatigue,
chest pain, and fainting [2]. Although there is no cure for
PAH, pharmacotherapy may be used to manage the disease
and improve symptoms [4]. Several classes of pharmaco-
therapy are available to treat PAH: endothelin receptor an-
tagonists (bosentan and ambrisentan); phosphodiesterase
type 5 inhibitors (sildenafil and tadalafil); and prostacyclin
analogues (epoprostenol, treprostinil and iloprost) [11].
Studies have demonstrated that combination therapy with
2 or more medications from different classes may provide
benefit over monotherapy [12,13]. As symptoms of PAH
are similar to those of other diseases, diagnosis may be de-
layed until more advanced disease stage, when treatment is
not as successful [14]. Surgical intervention, such as lung
transplant or balloon atrial septostomy, may be needed for
patients who are not adequately controlled with medica-
tion [4].
PAH is a rare but costly disease. The prevalence of PAH
in the US has been estimated at 109 per million among in-
dividuals under 65, and 451 per million among individuals
65 and over [15]. Limited information is available regard-
ing real-world health care resource utilization patterns
and costs among PAH patients in the US, in part due to
the difficultly in identifying PAH using administrative
claims data. Copher et al. reported average all-cause health
care costs among patients with PAH at $9,295 per-
patient-per-month (PPPM) [16], Angalakuditi reported
average PAH-related health care costs at $4,236 PPPM
[17], Said et al. reported average total health care costs
among patients with PAH at $4,021 PPPM [18], and
Kirson et al. reported average PPPM direct health care
costs for PAH at $2,023 [19]. As existing ICD-9-CM codes
may not be specific enough to distinguish PAH from other
related conditions, prior studies have used a variety of
approaches and different combination of claims-based
evidence to identify PAH patients from administrative da-
tabases, including diagnosis claims for PH, evidence of a
right heart catheterization, and claims for medications
used to treat PAH.
The objective of this study was to explore the health care
costs and resource utilization associated with PAH in a
large, national US managed care health plan using contem-
porary real-world data with a substantial time frame (five
and one-half years). In this study, we required that PAH
subjects have claims-based evidence of PAH-indicated
medications, PH diagnoses, and PAH-related diagnoses in
order to make subject selection as specific as possible. By
setting the index date as the earliest date of evidence for aPAH-indicated medication (and then performing compari-
sons between the baseline and follow-up periods), we
hoped to gain additional insight into how PAH medication
use may influence total health care costs among PAH pa-
tients. Additionally, in this study we examined both health
plan and patient paid costs, to better understand the eco-
nomic burden on payers and patients, respectively.
Methods
Data source and subject selection
This study used administrative claims of commercial and
Medicare Advantage enrollees with Part D prescription drug
coverage from a large national managed care organization.
During the period of the study, the database contained ap-
proximately 41.7 million members with continuous med-
ical and pharmacy benefits (and approximately 14 million
total covered lives per year). The geographic makeup of
individuals covered by the health plan was diverse, with
services rendered in all major regions of the United States.
No identifiable protected health information was extracted
or accessed during the course of the study. Pursuant to
the Health Insurance Portability and Accountability Act
[20], the use of de-identified data does not require Institu-
tional Review Board approval or waiver of authorization,
and research involving the collection or study of already
existing de-identified data does not require patient con-
sent [21].
Subjects were initially identified from the database who
had at least 1 claim during the period from 01 January
2004 to 30 June 2010 (defined as the identification period)
for either a PAH-indicated study medication (bosentan,
ambrisentan, tadalafil [Adcirca®], sildenafil [Revatio®], ilo-
prost, treprostinil, epoprostenol); an ICD-9-CM diagnosis
code in any position for primary pulmonary hypertension
(416.0) or other chronic pulmonary heart diseases (416.8);
or a diagnosis code in any position for a PAH-associated
condition (connective tissue diseases, congenital heart
diseases, portal hypertension; codes in Additional file 1:
Table S1). After this initial selection step, subjects who
had ≥2 claims with a primary PH diagnosis, ≥2 claims with
a PAH-related diagnosis (of which ≥1 primary), and ≥1
claim with evidence for a PAH-indicated medication were
selected for the final study sample (Figure 1). The index
date for the final study sample was designated as the earli-
est date of a medical or pharmacy claim with evidence of
PAH-indicated medication in the identification period.
For inclusion in the final study sample subjects were re-
quired to be continuously enrolled during a 180-day base-
line period before the index date, and for an additional
365-day follow-up period starting on and including the
index date.
Exploratory analyses were also performed, in which sub-
jects were also eligible for selection into two subgroups
with less stringent inclusion criteria: a PAH diagnosis
Subgroups not mutually exclusive
Subjects Continuously Enrolled During  
Study Period
N=4,332 (PAH Diagnosis Group)
Subjects Continuously Enrolled During  
Study Period
N=1,719 (PAH Medication Group)
Unique Subjects in Database
From 1/1/2004 to 6/30/2010 
N=41,666,589
Subjects with at least one claim for either
a) a PAH-indicated medication OR
b) a PH diagnosis OR
c) a PAH-related diagnosis
N=900,597
Subjects with ≥2 claims with a PH Diagnosis  
and ≥1 claim with a PAH-related Diagnosis
N=8,899
Subjects with ≥1 Claim for a PAH-indicated
Medication
N=4,080
Subjects with ≥2 PH DiagnosisClaims 
and ≥2 PAH-Related DiagnosisClaims 
N=504 (Final Study Sample)
Figure 1 Selection of subjects with PAH.
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subjects between the PAH diagnosis group and the PAH
medication group was allowed. Criteria required for inclu-
sion in the PAH diagnosis group were evidence of ≥2
medical claims with a PH diagnosis code at least 15 days
apart (of which ≥1 was in the primary position) and ≥1
medical claim with a (primary or secondary) PAH-related
diagnosis during the identification period. The index date
for the PAH diagnosis group was designated as the earliest
date of a medical claim with a diagnosis code in any pos-
ition for either PH or a PAH-related condition during
the identification period. Inclusion in the PAH medi-
cation group required ≥1 instance of evidence for a
PAH-indicated medication. The index date for the
PAH medication group was designated as the earliest
date of a medical or pharmacy claim with evidence of
PAH-indicated medication in the identification period.
Subjects in both the PAH diagnosis group and the
PAH medication group were required to be continu-
ously enrolled during a 180-day baseline period before
the index date, and for an additional 365-day follow-
up period starting on and including the index date.
Age, gender, and geographic region (Northeast, South,
West, or Midwest) were captured from enrollment databased on the claim used to identify the index date. Co-
morbidities were identified based on the presence of
diagnosis and/or service codes on medical claims during
the baseline and follow-up periods, using AHRQ classifi-
cations [22]. Each AHRQ category was comprised of a
series of diagnosis codes corresponding to similar dis-
ease conditions. Presence of any code within a given cat-
egory in any position during a given time period would
set the indicator variable to 1. In contrast, absence of all
codes within a category across all claims during a given
time period would set the indicator variable to 0.
Health care costs and resource utilization
Health care resource utilization and costs were captured
in the baseline and follow-up periods. The baseline con-
tinuous measures were annualized, to provide compar-
able metrics to the follow-up period. Health care costs
were computed as the combined health plan and patient
paid amounts; in addition, payments from Medicare (or
other payers) were estimated based on coordination of
benefits information obtained by the health plan, and
these estimates were incorporated into the total paid
amount. The following cost variables were calculated: total
costs, pharmacy costs, and medical costs. Medical costs
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gency services costs, inpatient costs, and other medical
costs. Costs were presented as total (health plan plus pa-
tient paid), health plan paid and patient paid. Patient paid
costs were comprised of the fixed amount that a member
paid for a specific service as defined in their benefit plan,
the amount that was applied towards the member’s de-
ductible, and any additional dollars paid by a member at
the pharmacy (above copay, coinsurance or deductible).
Procedures, drug dispensings, and doctor visits that oc-
curred during an inpatient admission were included in the
costs for that admission (the same applied to costs in-
curred during an emergency department or ambulatory
visit). Costs were adjusted to 2011 US$ using the annual
medical care component of the Consumer Price Index.
Health care resource utilization was operationalized as the
numbers of the following: ambulatory visits, emergency
department visits, and inpatient admissions. Comparisons
of continuous variables were made using signed rank test.
All software analyses were conducted in SAS 9.2.
Medication use and treatment patterns
Medications that could be used to treat PAH were iden-
tified from pharmacy claims (using National Drug Code
[NDC] code bundles) and medical claims (using appro-
priate Healthcare Common Procedure Coding System
[HCPCS] codes submitted by individual providers which
use the Health Care Financing Administration [HCFA]-
1500 or Centers for Medicare and Medicaid Services
[CMS]-1500 formats or for facility services submitted by
institutions, which use the Uniform Bill [UB]-82, UB-92,
UB-04, or CMS-1450 formats). Medication use was cap-
tured separately in both the baseline and follow-up
periods.
Medication treatment patterns were captured across
follow-up period pharmacy claims, and only for those
subjects who had evidence of a single PAH-indicated
study medication in the first 30 days of the follow-up
period. Discontinuation of index therapy was defined as
the earliest gap (if multiple exist) in therapy of >60 days
between the “run out” of days supplied from the previ-
ous prescription (i.e., prescription fill date + days sup-
plied – 1) to the fill date of the next prescription or the
end of follow-up. If a subject had a 60-day gap in index
therapy, the discontinuation date was noted as the run
out date. Subjects whose last run out date in a series of
continuous use was within 60 days of the end of the
study period were considered continuous users of ther-
apy with no evidence of discontinuation. Switches from
index PAH treatment at the time of discontinuation
were assessed. A switch in therapy was defined as a filled
prescription for a new PAH medication that occurred
within 60 days prior to or following the date of index
PAH medication discontinuation. PAH treatment add-ons were identified for patients adding new PAH therap-
ies to their index therapy while continuing use of index
therapy. Add-on was defined as the addition of a new
PAH medication other than the index medication at
least 60 days prior to the date of discontinuation or
60 days prior to the end of the study period if there was
no evidence of discontinuation. Subjects who did not
discontinue, switch, or add-on to their index therapy
were classified as having maintenance of index therapy.
Finally, the medication possession ratio (MPR) was cap-
tured and reported separately for each PAH index ther-
apy. MPR was defined as the proportion of follow-up
days with the index therapy available based on fill dates
and day supply given on the pharmacy claims. MPR was
calculated as the number of non-inpatient days where
the medication of interest was available (numerator) di-
vided by the total number of non-inpatient days (de-
nominator). MPR was captured until discontinuation for
subjects who discontinued; for those who didn’t discon-
tinue, MPR was captured during the entire 12 month
follow-up period.
Results
In total, there were 41,666,589 enrollees in the health
plan during the study period. Of these, 504 PAH subjects
who met continuous enrollment criteria and had claims-
based evidence of PAH-indicated medications, PH diag-
noses, and PAH-related diagnoses were selected for the
final study sample (Figure 1). In the final PAH study
sample, subjects had an average age of 49.73 years, and
23.21% of subjects were male. Approximately three-
quarters of subjects were from either the South or Mid-
west (which reflects the geographic distribution of health
plan enrollees), and 87.10% of subjects had commercial
insurance (Table 1). The most frequently observed co-
morbidities, based on claims data, were diseases of the
heart (97.42% of subjects), lower respiratory disease
(85.91%), hypertension (59.13%), diseases of arteries, ar-
terioles, and capillaries (52.98%), and systemic lupus ery-
thematosus and connective tissue disorders (51.79%)
(Table 1). We note that some comorbidities identified
here, such as diseases of the heart and lower respiratory
diseases, are symptoms of PAH. It is likely that the co-
morbidity profile is partly a reflection of the PAH-
associated conditions included in the subject identifica-
tion algorithm.
Among patients in the final study cohort (N = 504),
the average of the total annual health care costs were
higher in the baseline period ($116,681 [SD = 368,094])
vs. the follow-up period ($98,243 [SD = 110,615]) (p <
0.001) (Figure 2). Whereas the average medical costs
were significantly higher in the baseline period vs. the
follow-up period ($110,241 [SD = 368,725] vs. $59,729
[SD = 106,683], p = <0.001), the average pharmacy costs
Table 1 Subject demographic and clinical characteristics
Final PAH study
sample (N = 504)
Mean SD
Age, years 49.73 19.79
n %










Diseases of the heart 491 97.42
Lower respiratory disease 433 85.91
Hypertension 298 59.13
Diseases of arteries, arterioles, and capillaries 267 52.98
Systemic lupus erythematosus and
connective tissue disorders
261 51.79
Respiratory infections 188 37.30
Upper gastrointestinal disorders 182 36.11
Non-traumatic joint disorders 181 35.91
Connective tissue disease 170 33.73
Injuries and conditions due to external causes 163 32.34
Diseases of the urinary system 162 32.14
Chronic obstructive pulmonary disease
and bronchiectasis
156 30.95
Disorders of lipid metabolism 153 30.36
Gastrointestinal disorders 141 27.98
Cardiac and circulatory congenital anomalies 136 26.98
Anemia 133 26.39
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the follow-up period ($6,440 [SD = 12,187] vs. $38,514
[SD = 34,817], p < 0.001). Among medical costs, the aver-
ages of the inpatient costs were significantly higher in the
baseline period vs. the follow-up period ($81,577 [SD =
357,009] vs. $26,297 [SD = 77,462], p < 0.001). The aver-
age ER costs were similar between the baseline period vs.
the follow-up period ($488 [SD = 1,252] vs. $541 [SD =
1,774], p = 0.700), and average ambulatory costs were
slightly higher in the baseline period vs. the follow-up
period ($20,786 [SD = 49,781] vs. $18,098 [SD = 48,152],
p < 0.001). In general, similar trends were observed when
limiting analysis to health plan paid or patient paid costs.
For both patient paid and health plan paid costs,medical costs were significantly higher in the baseline
period vs. the follow-up period, whereas pharmacy costs
were significantly lower in the baseline period vs. the
follow-up period (Figure 3).
Patterns of health care resource utilization between the
baseline period and follow-up period were consistent with
the patterns observed for health care costs. Average annual
counts of inpatient stays (1.38 [SD = 2.03] vs. 0.91 [SD =
1.59], p < 0.001), ambulatory visits (44.95 [SD = 26.86] vs.
41.62 [28.71], p < 0.001), and ER visits (1.56 [SD = 2.95] vs.
1.55 [SD = 3.17], p = 0.032) were higher in the baseline
period vs. the follow-up period (Table 2). During the
follow-up period, the most commonly used PAH-indicated
medications were sildenafil (Revatio), used by 51% of sub-
jects, and bosentan, used by 46% of subjects (Figure 4).
About 31% of subjects had evidence of using more than
one PAH-indicated medication during the follow-up
period (data not shown). Treatment patterns were exam-
ined in greater detail using pharmacy claims for those sub-
jects who had claims for only a single PAH medication
during the first 30 days of follow-up (N = 425). Within this
group, maintenance of the index therapy regimen was
observed for 52.71% of subjects, and discontinuation
was observed for 38.12% of subjects (Table 3). Of subjects
who discontinued, 14.20% had evidence of switching from
the index medication. Also, 11.06% of subjects had evi-
dence of adding to the index medication. Average MPRs
were over 0.90 for each individual PAH medication mea-
sured (standard deviations all < 0.13), except for iloprost
(0.86 [SD = 0.21]), indicating good overall adherence to
medication.
In exploratory analyses that had less restrictive inclusion
criteria, 4,332 subjects were selected who met continuous
enrollment criteria and had claims-based evidence of PH
diagnoses and a PAH-related diagnosis (PAH diagnosis
group), and 1,719 subjects were selected who met con-
tinuous enrollment criteria and had claims-based evidence
of a PAH-indicated medication (PAH medication group)
(Figure 1). Average total baseline and follow-up health
care costs among both the PAH medication group and the
PAH diagnosis group were substantively lower than
was observed among subjects in the final study cohort
(Figure 5). Trends observed in the PAH medication group
exploratory analysis were similar to those for the final
study sample. In the PAH medication group analysis,
medical costs were significantly higher in the baseline vs.
the follow-up period (p < 0.001), while pharmacy costs
were significantly higher in the follow-up vs. baseline
period (p < 0.001) (Figure 5). However, in the PAH diagno-
sis group exploratory analysis (where the index date was
set based on a diagnosis claim, not a PAH medication
claim), total costs, pharmacy costs, and medical costs were
all higher in the follow-up period vs. the baseline period



































Final PAH Study Sample (N=504)
Figure 2 Average health care costs (annualized baseline and 12 month follow-up). Differences in costs between baseline and follow-up
were statistically significant (p < 0.001) for all categories, with the exception of ER costs (p = 0.700). Bars represent standard deviation.
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In this study we investigated the health care costs and
resource use associated with PAH using a large, national
US managed care health plan database. The index date
in this study was set as the earliest date of evidence for a
PAH-indicated medication, and health care costs were
compared before and after the index date. Cost estimates
for PAH in the final study sample were substantively
high, and were calculated to be $116,681 in the baseline
period and $98,243 in the follow-up period. We found
that although pharmacy costs increased significantly from
the baseline to follow-up period, medical costs decreased
significantly from the baseline to follow-up period. The
decrease in medical costs appeared to be driven primarily
by inpatient costs, which decreased by more than two-
thirds from baseline to follow-up. Importantly, the index
date for the final PAH study cohort was set as the earliest
date of a claim with evidence of PAH-indicated medica-
tion during the identification period. A possible interpret-
ation of these trends is that although medication costs
for PAH subjects are high, pharmaceutical management
with a PAH-indicated medication is associated with a re-
duction in medical costs among subjects with disease.
However, due to the observational study design, it was not
possible to establish a direct causal relationship between
PAH medication use and pre-index/post index changes,
such as a reduction in medical costs.
The differences observed for health care costs were
reflected in health-care resource utilization estimates, as
average counts of ambulatory visits, inpatient stays, and
ER visits were lower in the follow-up period vs. the base-
line period. Sildenafil (Revatio®) and bosentan were the
most commonly prescribed PAH medications during the
follow-up period among subjects in the final PAH studysample. Although evidence of PAH-indicated medication
use appeared to offer benefit in this sample (based on
health care cost and resource use trends from baseline
to follow-up), only about half of PAH subjects main-
tained their index medication regimen. Discontinuation
of the index regimen was observed for about 38% of
subjects, and about 11% of subjects had evidence of aug-
mentation. Future research could investigate PAH costs
and treatment patterns among specific subgroups of pa-
tients, such as a patient population stratified by age or a
population stratified by gender.
Several prior studies have investigated the economic
burden of PAH in the US. The total health care costs
among PAH subjects reported in this study are higher
than those reported by Said et al. In a retrospective
study using administrative claims data, Said et al. found
that the total health care costs of PAH patients identified
from 2004–2009 were $4,021 per-patient-per-month
(PPPM) [18]. By comparison, we found that average total
health care costs were about $98,243 for the 12 month
follow-up period (or about $8,187 per month). Unlike
this study, Said et al. required evidence of right heart
catheterization or echocardiogram for subject inclusion.
Importantly though, Said et al. did not require evidence of
a PAH-indicated medication for subject inclusion, whereas
we required that subjects have at least one claim for a
PAH-related medication for inclusion in the final sample.
This may in part explain the difference in costs between
studies, as further analyses performed here indicated that
the PAH-indicated medication requirement appeared to
be more specific than the PH/PAH-associated diagnosis
code requirement in selecting PAH subjects. Similarly,
Kirson et al. reported that average PPPM costs among
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ER Costs Other Medical
Costs
Final PAH Study Sample (N=504) Patient Paid Costs
Baseline
Follow-Up
Figure 3 Average health plan and patient paid health care costs (annualized baseline and 12 month follow-up). For health plan paid
costs, differences in costs between baseline and follow-up were statistically significant (p < 0.001) for all categories, with the exception of ER costs
(p = 0.653). For patient paid costs, differences in costs between baseline and follow-up were statistically significant (p < 0.001) for all categories,
with the exception of total costs (p = 0.989) and ER costs (p = 0.758). Bars represent standard deviation.
Table 2 Health care resource utilization (annualized baseline and 12 month follow-up)
Final PAH study sample (N = 504)
Baseline Follow-up p-value
Mean SD Median Mean SD Median
Health care utilization counts
Ambulatory visits 44.95 26.86 42.58 41.62 28.71 36.00 <0.001
Office visits 26.17 18.74 22.31 24.63 18.01 21.00 0.010
Outpatient visits 19.19 16.56 16.22 17.34 18.49 12.00 <0.001
ER visits 1.56 2.95 0.00 1.55 3.17 0.00 0.032
Inpatient stays 1.38 2.03 0.00 0.91 1.59 0.00 <0.001

















Final PAH Study Sample (N=504)
Figure 4 PAH medication use (12 month follow-up).
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medication for subject inclusion [19]. The costs reported
by Said et al. and Kirson et al. are closer to the costs re-
ported here in the exploratory analysis for the PAH diag-
nosis group ($51,395 for the 12 month follow-up, or about
$4,283 per month).
However, the costs reported in the present study are
similar to costs for PAH determined by Copher et al. In
a retrospective claims-based analysis, Copher et al. re-
ported that the total health care costs of PAH patients
identified from 2004–2008 were $9,295 per-patient-per-
month [16], which is slightly higher than our estimate ofTable 3 PAH medication treatment patterns (12 month
follow-up)
PAH subjects1 (N = 425)
n %
Discontinuation of index therapy regimen 162 38.12
Switch from index therapy regimen2 23 14.20
Augmentation to index therapy regimen 47 11.06
Maintenance of index therapy regimen 224 52.71






Tadalafil (Adcirca®) 22 0.94
Sildenafil (Revatio®) 191 0.92
1Of the subjects in the final sample, 425 were monotherapy pharmacy users in
the 30 days following the index date; these subjects were included in the analysis
of follow-up treatment patterns.
2Percentage of switchers calculated out of subjects who discontinued (n = 162).about $8,187 per month. Similar to the present study,
Copher et al. required both a PH diagnosis and evidence
of PAH medication use for study inclusion. However, they
also required evidence of a right heart catheterization or
pulmonary hypertension-related inpatient stay for study
inclusion, whereas PAH-related diagnosis claims were re-
quired in the present study. Similar to the present study,
Copher et al. found that sildenafil and bosentan were the
most common index medications. However, Copher et al.
did not compare medical costs before and after an index
medication date. In the present study, we found that med-
ical costs were significantly lower in the follow-up period,
compared with the baseline period, suggesting that PAH
medication use may affect the costs associated with treat-
ing PAH. Angalakuditi et al. also included evidence of
PAH-indicated medication in their subject identifica-
tion algorithm (patients were identified from 2006–2008).
However, Angalakuditi et al. reported on PAH-related
healthcare costs ($4,236 PPPM) [17], and not all-cause
costs as reported in the present study, so direct compari-
son between studies is not possible. Also, cost estimates in
Angalakuditi et al. were limited to subjects with bosentan
or sildenafil as the index medication. While bosentan and
sildenafil appeared to be the two most commonly pre-
scribed medications in the present study, PAH subjects
who had evidence of using other medications (ambrisen-
tan, tadalafil, iloprost, treprostinil, epoprostenol) were also
included in the present study. In another recent study
using a patient identification period from 2005–2008,
Berger et al. compared medical and pharmacy costs of
PAH patients before and after initiating sildenafil [23]. In
comparisons between 6 month pretreatment and follow-
up periods, Berger et al. reported an increase in pharmacy
costs ($9,853 vs. $16,971), and a decrease in medical costs
































































PAH Diagnosis Group (N=4,332)
Figure 5 PAH medication group and PAH diagnosis group average annual health care costs (exploratory analysis). For PAH medication
group, differences in costs between baseline and follow-up were statistically significant (p < 0.01) for all categories. For PAH diagnosis group,
differences in costs between baseline and follow-up were statistically significant (p < 0.001) for all categories. Bars represent standard deviation.
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was similar to the study design employed here, Berger
et al. limited the index medication to sildenafil, whereas a
variety of PAH-indicated medications were allowed as the
index medication in the present study. Differences in cost
comparisons among studies could also be due to inflation,
as studies used different time periods for subject identifi-
cation. Although we are not aware of studies from coun-
tries other than the US that have used a similar study
design and could be directly compared to the results of
this study, Wilkens et al. reported the overall treatment
costs of PAH in Germany at 47,400 EUR per-patient-per-
year (or about $65,000) among patients receiving treatment
from 2004–2006, which is lower than total health care costs
reported here [24].
Certain data limitations that are inherent to claims-
based analyses should be considered when interpretingthe results of this study. Claims data are collected for
the purpose of payment, not research, and therefore cap-
ture an individual’s medical history to a limited degree.
Claims data do not contain detailed information on symp-
toms, no self-reported burden of illness measures were
obtained in this study, and quality of life measures were
not available. Importantly, existing ICD-9-CM codes may
not be specific enough to distinguish PAH from other
related conditions, and it is therefore difficult to locate
subjects with PAH in administrative claims. Based on ex-
ploratory analyses, we found that requiring evidence of a
PAH-indicated medication appeared to be a more specific
inclusion criterion than requiring PH/PAH-associated
diagnosis codes. Average total health care costs among the
PAH medication group and PAH diagnosis group were
both lower than was observed among subjects in the final
study cohort. This suggests that some of the subjects selected
Sikirica et al. BMC Health Services Research  (2014) 14:676 Page 10 of 11in these exploratory analyses may have had earlier/pre-
treatment stages of PAH, and/or perhaps suggests that the
selection criteria for these analyses were not specific
enough, in comparison to the final algorithm. It is import-
ant to keep in mind that the PAH medication group and
the PAH diagnosis group were performed as exploratory
analyses; they each incorporated different subsets of selec-
tion criteria used for the final study cohort, but were not
intended to be as specific as the final study cohort. For in-
clusion in the final study cohort, we used a claims-based
algorithm requiring evidence of a PAH-indicated medica-
tion, PH diagnosis codes, and PAH-associated condition
diagnosis codes, in order to increase specificity of selection.
However, further research, such as a medical chart review,
would be needed to validate the claims-based patient iden-
tification algorithm used here.
No comparisons were performed in this study using a
control group that did not have PAH, and this is a further
study limitation. As we required a period of 12 months of
continuous enrollment following the index date for study
inclusion, patients who died shortly following the index
date would have been excluded from the study, and this
may have impacted cost estimates. Also, measures from
the 180 day baseline period were annualized, and this may
have introduced some bias into the results. Cost and re-
source utilization estimates may also have been impacted
by comorbid diseases. We observed high rates of some co-
morbid diseases in this population, such as systemic lupus
erythematosus and respiratory infections, and this may
have led to higher costs and utilization in some patients.
Finally, the results observed in this study are most applic-
able to a managed care population diagnosed with and be-
ing treated for PAH, and may not be generalizable to
other populations or to the US population in whole.
Additional limitations regarding pharmacy claims should
be considered. For example, it is not possible to determine
whether subjects consumed their medication as prescribed.
In addition, over-the-counter medications and medications
provided as samples by physicians cannot be located in
claims data. A small proportion of study subjects (6%) had
evidence of PAH medication use prior to the index date,
and this may have affected comparisons of costs between
the baseline and follow-up period (as on average lower
total costs were observed after PAH medication use). We
assumed that pharmacological treatment for PAH was a
strong indication that physicians believed their patients to
experience PAH (regardless of diagnosis coding), as the
medications used are indicated only for the treatment of
PAH (per the US package insert/ label, which note only
PAH as an indication). However, this assumption is most
at risk in the case of tadalafil and sildenafil, which are
branded as Adcirca® and Revatio® for treatment of PAH
only, but which are also formulations of generics that are
branded as Cialis® and Viagra®, respectively, which are notindicated for PAH. Likewise, another caveat is that some
off label use of Cialis® and Viagra® may occur, and patients
who used these medications to manage PAH were not in-
cluded in this study. Pharmacy claims for the managed
Medicare population also present certain limitations. Prior
to 2006, managed Medicare enrollees had pharmacy cov-
ered through their health plan, one of the benefits of en-
rollment in certain managed Medicare plans. However, for
a portion of these enrollees, these pharmacy benefits had
caps on expenditures. Enrollees with substantial pharmacy
expenditures may have exceeded their cap in certain years.
For these members, additional filled prescriptions may not
be observed in the claims data, and it would appear that
these individuals ceased to fill prescriptions. This limita-
tion may have impacted the findings we report for treat-
ment patterns.
Conclusions
The results from this study indicate that medical costs
decreased by nearly half from the baseline to the follow-
up period (following evidence of use of PAH medica-
tion). However, annual total follow-up costs among PAH
patients reported here were still substantively high on a
per subject basis. Further, this study found that about
half of subjects with PAH discontinued, switched, or
augmented their index PAH medication. Further re-
search is needed to examine whether the treatment pat-
terns revealed in this study represent clinically optimal
or cost-effective care.Additional file
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